Compare Incyte Corporation (INCY) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Stitch Fix Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Stitch Fix Inc trades at $3.79 (market cap $497.68M). The key difference: Incyte Corporation is far larger — about 49.3× Stitch Fix Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| INCY | SFIX | |
|---|---|---|
Market Cap | $24.54B | $497.68M |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $5.83 |
52-Week Low | $81.61 | $3.06 |
Enterprise Value | $20.04B | $385.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Stitch Fix (SFIX) trades at $3.54, down 10.83% over 24 hours, reflecting recent market pressure. The stock shows a bullish technical signal with key moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, revenue stabilized at $1.27B in 2025, with net losses narrowing significantly to -$28.74M, indicating progress toward profitability. Recent news highlights AI-driven personalization tools and exclusive brand collaborations as growth catalysts.
The outlook suggests a potential rebound opportunity, supported by a consensus price target of $4.75 (34% upside). However, risks include persistent net losses, competitive pressures in retail, and sensitivity to consumer spending trends. Analyst sentiment is mixed, with 27% buy ratings but 64% hold, signaling cautious optimism amid the company's turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
